Antioxidant and antiinflammatory activities of curcumin on diabetes mellitus and its complications

Current Pharmaceutical Design

Volumn 19, Issue 11, 2013, Pages 2101-2113

  Meng, Bo ^a   Li, Jun ^a   Cao, Hong ^a  

^a THE SECOND AFFILIATED HOSPITAL AND YUYING CHILDREN S HOSPITAL OF WENZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Curcumin; Diabetes mellitus; Inflammatory cytokines; Oxidative stress

Indexed keywords

ANTIINFLAMMATORY AGENT; ANTIOXIDANT; ATORVASTATIN; BIS OHYDROXYCINNAMOYL METHANE; CURCUMIN; CURCUMINOID DERIVATIVE; CYTOKINE; DIDEMETHOXYCURCUMIN; NCB 02; TETRAHYDROCURCUMIN; UNCLASSIFIED DRUG;

ANTIDIABETIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; BRAIN DISEASE; CYTOKINE RELEASE; DIABETES MELLITUS; DIABETIC ANGIOPATHY; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG ELIMINATION; DRUG METABOLISM; DRUG TARGETING; GLUCOSE METABOLISM; HISTONE ACETYLATION; HUMAN; INFLAMMATION; LIPID METABOLISM; LIPID PEROXIDATION; LIVER TOXICITY; NONHUMAN; OXIDATIVE STRESS; PANCREAS ISLET BETA CELL; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; WOUND HEALING;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIOXIDANTS; BIOLOGICAL MARKERS; BLOOD GLUCOSE; CURCUMIN; DIABETES COMPLICATIONS; DIABETES MELLITUS; HUMANS; HYPOGLYCEMIC AGENTS; INFLAMMATION MEDIATORS; INSULIN-SECRETING CELLS; OXIDATIVE STRESS; TREATMENT OUTCOME;

EID: 84875386452     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: None     Document Type: Review

References (151)

1. Danaei G, Finucane MM, Lu Y, et al. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants. Lancet 2011; 378: 31-40.
2. Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract 2010; 87: 4-14.
3. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001; 414: 813-820.
4. González EL, Johansson S, Wallander MA, Rodríguez LA. Trends in the prevalence and incidence of diabetes in the UK: 1996-2005. J Epidemiol Community Health 2009; 63: 332-336.
5. Porte D Jr. Clinical importance of insulin secretion and its interaction with insulin resistance in the treatment of type 2 diabetes mellitus and its complications. Diabetes Metab Res Rev 2001; 17: 181-188.
6. Froguel P, Velho G. Genetic determinants of type 2 diabetes. Recent Prog Horm Res 2001; 56: 91-105.
7. Evans JL, Goldfine ID, Maddux BA, Grodsky GM. Oxidative Stress and Stress-Activated Signaling Pathways: A Unifying Hypothesis of Type 2 Diabetes. Endocr Rev 2002; 23: 599-622.
8. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. CReactive Protein, Interleukin 6, and Risk of Developing Type 2 Diabetes Mellitus. JAMA 2001; 286: 327-34.
9. Wellen KE, Hotamisligil GS. Inflammation, stress, and diabetes. J Clin Invest 2005; 115: 1111-1119.
10. Nolan CJ, Damm P, Prentki M. Type 2 diabetes across generations: from pathophysiology to prevention and management. Lancet 2011; 378: 169-181.
11. Brownlee M. Biochemistry and molecular cell biology of diabetic complications.Nature 2001; 414: 813-820.
12. Brownlee M. Negative consequences of glycation. Metabolism 2000; 49: 9-13.
13. Halliwell B. Free radicals, antioxidants, and human disease: curiosity, cause, or consequence? Lancet 1994; 344: 721-724.
14. Thornalley PJ, McLellan AC, Lo TW, Benn J, Sönksen PH. Negative association between erythrocyte reduced glutathione concentration and diabetic complications. Clin Sci (Lond) 1996; 91: 575-582.
15. Baynes JW. Role of oxidative stress in development of complications in diabetes. Diabetes 1991; 40: 405-412.
16. Yamagishi SI, Edelstein D, Du XL, Kaneda Y, Guzmán M, Brownlee M. Leptin induces mitochondrial superoxide production and monocyte chemoattractant protein-1 expression in aortic endothelial cells by increasing fatty acid oxidation via protein kinase A. J Biol Chem 2001; 276: 25096-25100.
17. Hayden MS, Ghosh S. Signaling to NF-kappaB. Genes Dev 2004; 18: 2195-2224.
18. Perkins ND. Post-translational modifications regulating the activity and function of the nuclear factor κB pathway. Oncogene 2006; 25: 6717-6730.
19. Zick, Y. Role of Ser/Thr kinases in the uncoupling of insulin signaling. Int J Obes Relat Metab Disord 2003; 27 (Suppl 3): S56-S60.
20. Emanuelli B, Peraldi P, Filloux C, et al. SOCS-3 inhibits insulin signaling and is up-regulated in response to tumor necrosis factoralpha in the adipose tissue of obese mice. J iol Chem 2001; 276: 47944-47949.
21. Li Y, Reddy MA, Miao F, et al. Role of the Histone H3 Lysine 4 Methyltransferase, ET7/9, in the Regulation of NF-κB-dependent Inflammatory Genes: Relevance To Diabetes And Inflammation. J Biol Chem 2008; 283: 26771-26781.
22. Cai D, Yuan M, Frantz DF, et al. Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NFkappaB. Nat Med 2005; 11: 183-190.
23. Ozawa K, Miyazaki M, Matsuhisa M, et al. The endoplasmic reticulum chaperone improves insulin resistance in type 2 diabetes. Diabetes 2005; 54: 657-663.
24. Nakatani Y, Kaneto H, Kawamori D, et al. Involvement of endoplasmic reticulum stress in insulin resistance and diabetes. J Biol Chem 2005; 280: 847-851.
25. Furukawa S, Fujita T, Shimabukuro M, et al. Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest 2004; 114: 1752-1761.
26. Jin L, Xue HY, Jin LJ, Li SY, Xu YP. Antioxidant and pancreasprotective effect of aucubin on rats with streptozotocin-induced diabetes. Eur J Pharmacol 2008; 582: 162-167.
27. Aggarwal BB, Sundaram C, Malani N, Ichikawa H. Curcumin: the Indian solid gold. Adv Exp Med Biol 2007; 595: 1-75.
28. Syu WJ, Shen CC, Don MJ, Ou JC, Lee GH, Sun CM. Cytotoxicity of curcuminoids and some novel compounds from Curcuma zedoaria. J Nat Prod 1998; 61: 1531-1534.
29. Thapliyal R, Maru GB. Inhibition of cytochrome P450 isozymes by curcumins in vitro and in vivo. Food Chem Toxicol 2001; 39: 541-547.
30. Cheng AL, Hsu CH, Lin JK, et al. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or premalignant lesions. Anticancer Res 2001; 21: 2895-2900.
31. Chainani-Wu N. Safety and anti-inflammatory activity of curcumin: a component of tumeric (Curcuma longa). J Altern Complement Med 2003; 9: 161-168.
32. Anand P, Kunnumakkara AB, Newman RA, Aggarwal BB. Bioavailability of curcumin: problems and promises. Mol Pharm 2007; 4: 807-818.
33. Sharma RA, Gescher AJ, Steward WP. Curcumin: the story so far. Eur J Cancer 2005; 41: 1955-1968.
34. Shishodia S, Sethi G, Aggarwal BB. Curcumin: getting back to the roots. Ann N Y Acad Sc 2005; 1056: 206-217.
35. Pari L, Tewas D, Eckel J. Role of curcumin in health and disease. Arch Physiol Biochem 2008; 114: 127-149.
36. Duvoix A, Blasius R, Delhalle S, et al. Chemopreventive and therapeutic effects of curcumin. Cancer Lett. 2005, 223: 181-190.
37. Hamaguchi T, Ono K, Yamada M. REVIEW: Curcumin and Alzheimer's disease. CNS Neurosci Ther 2010; 16: 285-297.
38. Bright JJ. Curcumin and autoimmune disease. Adv Exp Med Biol 2007; 595: 425-451.
39. Alappat L, Awad AB. Curcumin and obesity: evidence and mechanisms. Nutr Rev 2010; 68: 729-738.
40. Aggarwal BB, Kumar A, Bharti AC. Anticancer potential of curcumin: preclinical and clinical studies. Anticancer Res 2003; 23: 363-398.
41. M Khopde S, Priyadarsini KI, Venkatesan P, Rao MN. Free radical scavenging ability and anti-oxidant efficiency of curcumin and its substituted analogue. Biophys Chem 1999; 80: 83-89.
42. Priyadarsini KI, Maity DK, Naik GH, et al. Role of phenolic O-H and methylene hydrogen on the free radical reactions and antioxidant activity of curcumin. Free Radic Biol Med 2003; 35: 475-484.
43. Sun YM, Zhang HY, Chen DZ, Liu CB. Theoretical elucidation on the anti-oxidant mechanism of curcumin: a DFT study. Org Lett 2002; 4: 2909-2911.
44. Okada K, Wangpoengtrakul C, Tanaka T, Toyokuni S, Uchida K, Osawa T. Curcumin and especially tetrahydrocurcumin ameliorate oxidative stress-induced renal injury in mice. J Nutr 2001; 131: 2090-2095.
45. Huang MT, Lysz T, Ferraro T, Abidi TF, Laskin JD, Conney AH. Inhibitory effects of curcumin on in vitro lipoxygenase and cyclooxygenase activities in mouse epidermis. Cancer Res 1991; 51: 813-819.
46. Sharma OP. Antioxidant activity of curcumin and related compounds. Biochem Pharmacol 1976; 25: 1811-1812.
47. Calabrese V, Bates TE, Mancuso C, et al. Curcumin and the cellular stress response in free radical-related diseases. Mol Nutr Food Res 2008; 52: 1062-1073.
48. Sajithlal GB, Chithra P, Chandrakasan G. Effect of curcumin on the advanced glycation and cross-linking of collagen in diabetic rats. Biochem Pharmacol 1998; 56: 1607-1614.
49. Nishizono S, Hayami T, Ikeda I, Imaizumi K. Protection Against the Diabetogenic Effect of Feeding tert-Butylhydroquinone to Rats Prior to the Administration of Streptozotocin. Biosci Biotechnol Biochem 2000; 64: 1153-1158.
50. Balasubramanyam M, Koteswari AA, Kumar RS, Monickaraj SF, Maheswari JU, Mohan V. Curcumin-induced inhibition of cellular reactive oxygen species generation: novel therapeutic implications. J Biosci 2003; 28: 715-721.
51. Bilmen JG, Khan SZ, Javed MH, Michelangeli F. Inhibition of the SERCA Ca2+ pumps by curcumin. Curcumin putatively stabilizes the interaction between the nucleotide-binding and phosphorylation domains in the absence of ATP. Eur J Biochem 2001; 268: 6318-6627.
52. Rukkumani R, Sri Balasubashini M, Vishwanathan P, Menon VP. Comparative effects of curcumin and photo-irradiated curcumin on alcohol- and polyunsaturated fatty acid-induced hyperlipidemia. Pharmacol Res 2002; 46: 257-264.
53. Mahesh T, Sri Balasubashini MM, Menon VP. Photo-irradiated curcumin supplementation in streptozotocin-induced diabetic rats effect on lipid peroxidation. Therapie 2004; 59: 639-634.
54. Mahesh T, Balasubashini MS, Menon VP. Effect of Photo- Irradiated Curcumin Treatment Against Oxidative Stress in Streptozotocin- Induced Diabetic Rats. J Med Food 2005; 8: 51-55.
55. Meghana K, Sanjeev G, Ramesh B. Curcumin prevents streptozotocin- induced islet damage by scavenging free radicals: a prophylactic and protective role. Eur J Pharmacol 2007; 577: 183-191.
56. Suarez-Pinzon WL, Mabley JG, Power R, Szabó C, Rabinovitch A. Poly (ADP-ribose) polymerase inhibition prevents spontaneous and recurrent autoimmune diabetes in NOD mice by inducing apoptosis of islet-infiltrating leukocytes. Diabetes 2003; 52: 1683-1688.
57. Suryanarayana P, Satyanarayana A, Balakrishna N. Effect of turmeric and curcumin on oxidative stress and antioxidant enzymes in streptozotocin-induced diabetic rat. Med Sci Monit 2007; 13: BR286-BR292.
58. Shirley SA, Montpetit AJ, Lockey RF, Mohapatra SS. Curcumin prevents human dendritic cell response to immune stimulants. Biochem Biophys Res Commun 2008; 374: 431-436.
59. Mona F. El-Azab, Fadia M. Attia, Abdalla M. El-Mowafy. Novel role of curcumin combined with bone marrow transplantation in reversing experimental diabetes: Effects on pancreatic islet regeneration, oxidative stress, and inflammatory cytokines. Eur J Pharmacol 2011; 658: 41-48.
60. Sugiyama Y, Kawakishi S, Osawa T. Involvement of the betadiketone moiety in the antioxidative mechanism of tetrahydrocurcumin. Biochem Pharmacol 1996; 52: 519-525.
61. Osawa T, Sugiyama Y, Inayoshi M. Antioxidative activity of tetrahydrocurcuminoids. Biosci Biotechnol Biochem 1995; 59: 1609-1612.
62. Raza H, Ahmed I, John A, Sharma AK. Modulation of xenobiotic metabolism and oxidative stress in chronic streptozotocin-induced diabetic rats fed with Momordica charantia fruit extract. J Biochem Mol Toxicol 2000; 14: 131-139.
63. Murugan P, Pari L. Antioxidant effect of tetrahydrocurcumin in streptozotocin-nicotinamide induced diabetic rats. Life Sci 2006; 79: 1720-1728.
64. Murugan P, Pari L. Effect of Tetrahydrocurcumin on Lipid Peroxidation and Lipids in Streptozotocin-Nicotinamide-Induced Diabetic Rats. Basic Clin Pharmacol Toxicol 2006; 99: 122-127.
65. Pari L, Murugan P. Changes in Glycoprotein Components in Streptozotocin - Nicotinamide Induced Type 2 Diabetes: Influence of Tetrahydrocurcumin from Curcuma longa. Plant Foods Hum Nutr 2007; 62: 25-29.
66. Murugan P, Pari L. Influence of tetrahydrocurcumin on erythrocyte membrane bound enzymes and antioxidant status in experimental type 2 diabetic rats. J Ethnopharmacol 2007; 113: 479-486.
67. Pari L, Karthikesan K, Menon VP. Comparative and combined effect of chlorogenic acid and tetrahydrocurcumin on antioxidant disparities in chemical induced experimental diabetes. Mol Cell Biochem 2010; 341: 109-117.
68. Ruby AJ, Kuttan G, Babu KD, Rajasekharan KN, Kuttan R. Antitumour and antioxidant activity of natural curcuminoids. Cancer Lett 1995; 94: 79-83.
69. Kim DS, Park SY, Kim JK. Curcuminoids from Curcuma longa L. (Zingiberaceae) that protect PC12 rat pheochromocytoma and normal human umbilical vein endothelial cells from betaA(1-42) insult. Neurosci Lett 2001; 303: 57-61.
70. Dinkova-Kostova AT, Talalay P. Relation of structure of curcumin analogs to their potencies as inducers of Phase 2 detoxification enzymes. Carcinogenesis 1999; 20: 911-914.
71. Srivivasan A, Menon VP, Periaswamy V, Rajasekaran KN. Protection of pancreatic β-cell by the potential antioxidant bisohydroxycinnamoyl methane, analogue of natural urcuminoid in experimental diabetes. J Pharm Pharm Sci 2003; 6: 327-333.
72. Woo HM, Kang JH, Kawada T, Yoo H, Sung MK, Yu R. Active spice-derived components can inhibit inflammatory responses of adipose tissue in obesity by suppressing inflammatory actions of macrophages and release of monocyte chemoattractant protein-1 from adipocytes. Life Sci 2007; 80: 926-931.
73. Weisberg SP, Leibel R, Tortoriello DV. Dietary Curcumin Significantly Improves Obesity-Associated Inflammation and Diabetes in Mouse Models of Diabesity. ndocrinology 2008; 149: 3549-3558.
74. Shanmugam N, Reddy MA, Guha M, Natarajan R. High-glucose- induced expression of proinflammatory cytokine and chemokine genes in monocytic cells. Diabetes 2003; 52: 1256-1264.
75. Yun JM, Jialal I, Devaraj S. Epigenetic regulation of high glucoseinduced proinflammatory cytokine productionin monocytes by curcumin. J Nutr Biochem 2011; 22: 450-458.
76. El-Moselhy MA, Taye A, Sharkawi SS, El-Sisi SF, Ahmed AF. The antihyperglycemic effect of curcumin in high fat diet fed rats. Role of TNF-a and free fatty acids. Food Chem Toxicol 2011; 49: 1129-1140.
77. Darville MI, Terryn S, Eizirik DL. An octamer motif is required for activation of the inducible nitric oxide synthase promoter in pancreatic beta-cells. Endocrinology 2004; 145: 1130-1136.
78. Kwon G, Corbett JA, Rodi CP, Sullivan P, McDaniel ML. Interleukin- 1 beta-induced nitric oxide synthase expression by rat pancreatic beta-cells: evidence for the involvement of nuclear factor kappa B in the signaling mechanism. Endocrinology 1995; 136: 4790-4795.
79. Kanitkar M, Gokhale K, Galande S, Bhonde RR. Novel role of curcumin in the prevention of cytokine-induced islet death in vitro and diabetogenesis in vivo. Br J Pharmacol 2008; 155: 702-713.
80. Jain SK, Rains J, Croad J, Larson B, Jones K. Curcumin supplementation lowers TNF-alpha, IL-6, IL-8, and MCP-1 secretion in high glucose-treated cultured monocytes and blood levels of TNFalpha, IL-6, MCP-1, glucose, and glycosylated hemoglobin in diabetic rats. Antioxid Redox Signal 2009; 11: 241-249.
81. Jain SK, Rains J, Jones K. Effect of curcumin on protein glycosylation, lipid peroxidation, and oxygen radical generation in human red blood cells exposed to high glucose levels. Free Radic Biol Med 2006; 41: 92-96.
82. Risbud MV, Bhonde RR. Models of pancreatic regeneration in diabetes. Diabetes Res Clin Pract 2002; 58: 155-165.
83. Mathews CE, Suarez-Pinzon WL, Baust JJ, Strynadka K, Leiter EH, Rabinovitch A. Mechanisms underlying resistance of pancreatic islets from ALR/Lt mice to cytokine-induced destruction. J Immunol 2005; 175: 1248-1256.
84. Rosenberg L, Rafaeloff R, Clas D, et al. Induction of islet cell differentiation and new islet formation in the hamster--further support for a ductular origin. Pancreas 1996; 13: 38-46.
85. Chanpoo M, Petchpiboonthai H, Panyarachun B, Anupunpisit V. Effect of curcumin in the amelioration of pancreatic islets in streptozotocin- induced diabetic mice. J Med Assoc Thai 2010; 93(Suppl 6): S152-S159.
86. urugan P, Pari L, Rao CA. Effect of tetrahydrocurcumin on insulin receptor status in type 2 diabetic rats: studies on insulin binding to erythrocytes. J Biosci 2008; 33: 63-72.
87. Pari L, Murugan P. Effect of tetrahydrocurcumin on blood glucose, plasma insulin and hepatic key enzymes in streptozotocin induced diabetic rats. J Basic Clin Physiol Pharmacol 2005; 16: 257-274.
88. The diabetes Control and complications trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993; 329: 977-986.
89. Arun N, Nalini N. Efficacy of turmeric on blood sugar and polyol pathway in diabetic albino rats. Plant Foods Hum Nutr 2002; 57: 41-52.
90. Halim Eshrat M. Ali Hussain. Hypoglycemic, hypolipidemic and antioxidant properties of combination of Curcumin from Curcuma longa, Linn, and partially purified product from Abroma augusta, Linn. in streptozotocin induced diabetes. Indian Journal of Clinical Biochemistry 2002; 17: 33-43.
91. Morrison RF, Farmer SR. Hormonal signaling and transcriptional control of adipocyte differentiation. J Nutr 2000; 130: 3116S-3121S.
92. Kuroda M, Mimaki Y, Nishiyama T, et al. Hypoglycemic effects of turmeric (Curcuma longa L. rhizomes) on genetically diabetic KKAy mice. Biol Pharm Bull 2005; 28: 937-939.
93. Nishiyama T, Mae T, Kishida H, et al. Curcuminoids and sesquiterpenoids in turmeric (Curcuma longa L.) suppress an increase in blood glucose level in type 2 diabetic KK-Ay mice. J Agric Food Chem 2005; 53: 959-963.
94. Kaplan F, Al-Majali K, Betteridge DJ. PPARS, insulin resistance and type 2 diabetes. J Cardiovasc Risk 2001; 8: 211-217.
95. Seo KI, Choi MS, Jung UJ, et al. Effect of curcumin supplementation on blood glucose, plasma insulin, and glucose homeostasis related enzyme activities in diabetic db/db mice. Mol Nutr Food Res 2008; 52: 995-1004.
96. Karthikesan K, Pari L, Menon VP. Combined treatment of tetrahydrocurcumin and chlorogenic acid exerts potential antihyperglycemic effect on streptozotocin-nicotinamide-induced diabetic rats. Gen Physiol Biophys 2010; 29: 23-30.
97. Reddy AC, Lokesh BR. Effect of curcumin and eugenol on ironinduced hepatic toxicity in rats. Toxicology 1996; 107: 39-45.
98. Babu PS, Srinivasan K. Influence of dietary curcumin and cholesterol on the progression of experimentally induced diabetes in albino: rat. Mol Cell Biochem 1995; 152: 13-21.
99. Suryanarayana P, Saraswat M, Mrudula T, Krishna TP, Krishnaswamy K, Reddy GB. Curcumin and turmeric delay streptozotocininduced diabetic cataract in rats. Invest phthalmol Vis Sci 2005; 46: 2092-2099.
100. Majithiya JB, Balaraman R. Time-dependent changes in antioxidant enzymes and vascular reactivity of aorta in streptozotocininduced diabetic rats treated with curcumin. J Cardiovasc Pharmacol 2005; 46: 697-705.
101. Babu PS, Srinivasan K. Hypolipidemic action of curcumin, the active principle of turmeric (Curcuma longa) in streptozotocin induced diabetic rats. Mol Cell Biochem 1997; 166: 169-175.
102. Kim M, Kim Y. Hypocholesterolemic effects of curcumin via upregulation of cholesterol 7a-hydroxylase in rats fed a high fat diet. Nutr Res Pract 2010; 4: 191-195.
103. Pari L, Murugan P. Antihyperlipidemic Effect of Curcumin and Tetrahydrocurcumin in Experimental Type 2 Diabetic Rats. Ren Fail 2007; 29: 881-889.
104. Karthikesan K, Pari L, Menon VP. Antihyperlipidemic effect of chlorogenic acid and tetrahydrocurcumin in rats subjected to diabetogenic agents. Chem Biol Interact 2010; 188: 643-650.
105. Jang EM, Choi MS, Jung UJ, et al. Beneficial effects of curcumin on hyperlipidemia and insulin resistance in high-fat-fed hamsters. Metabolism 2008; 57: 1576-1583.
106. Ejaz A, Wu D, Kwan P, Meydani M. Curcumin inhibits adipo genesis in 3T3-L1 dipocytes and angiogenesis and obesity in C57/BL mice. J Nutr 2009; 139: 919-25.
107. Kang Q, Chen A. Curcumin eliminates oxidized LDL roles in activating hepatic stellate cells by suppressing gene expression of lectin-like oxidized LDL receptor-1. Lab Invest 2009; 89: 1275-1290.
108. Roglic G, Unwin N, Bennett PH, et al. The burden of mortality attributable to diabetes: realistic estimates for the year 2000. Diabetes Care 2005; 28: 2130-2135.
109. Chan JC, Malik V, Jia W, et al. Diabetes in Asia: epidemiology, risk factors, and pathophysiology. JAMA 2009; 301: 2129-2140.
110. UK Prospective Diabetes Study (UKPDS) Group.Intensive bloodglucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352: 837-853.
111. Schalkwijk CG, Stehouwer CD. Vascular complications in diabetes mellitus: the role of endothelial dysfunction. Clin Sci (Lond) 2005; 109: 143-159.
112. Ceriello A, Assaloni R, Da Ros R, et al. Effect of atorvastatin and irbesartan, alone and in combination, on postprandial endothelial dysfunction, oxidative stress, and inflammation in type 2 diabetic patients. Circulation 2005; 111: 2518-2524.
113. Usharani P, Mateen AA, Naidu MU, Raju YS, Chandra N. Effect of NCB-02, atorvastatin and placebo on endothelial function, oxidative stress and inflammatory markers in patients with type 2 diabetes mellitus: a randomized, parallel-group, placebo-controlled, 8- week study. Drugs R D 2008; 9: 243-250.
114. Appendino G, Belcaro G, Cornelli U, et al. Potential role of curcumin phytosome (Meriva) in controlling the evolution of diabetic microangiopathy. A pilot study. Panminerva Med 2011; 53(3 Suppl 1): 43-49.
115. Rungseesantivanon S, Thenchaisri N, Ruangvejvorachai P, Patumraj S. Curcumin supplementation could improve diabetes-inducedendothelial dysfunction associated with decreased vascular superoxide production and PKC inhibition. BMC Complement Altern Med 2010; 10: 57.
116. Schrijvers BF, Flyvbjerg A, De Vriese AS. The role of vascular endothelial growth factor (VEGF) in renal pathophysiology. Kidney Int 2004; 65: 2003-2017.
117. Sawatpanich T, Petpiboolthai H, Punyarachun B, Anupunpisit V. Effect of curcumin on vascular endothelial growth factor expression in diabetic mice kidney induced by treptozotocin. J Med Assoc Thai 2010; 93(Suppl 2): S1-S8.
118. Javitt JC, Aiello LP, Chiang Y, Ferris FL 3rd, Canner JK, Greenfield S. Preventive eye care in people with diabetes is costsaving to the federal government. Implications for health-care reform. Diabetes Care 1994; 17: 909-917.
119. Mrudula T, Suryanarayana P, Srinivas PN, Reddy GB. Effect of curcumin on hyperglycemia-induced vascular endothelial growth factor expression in streptozotocin-induced diabetic rat retina. Biochem Biophys Res Commun 2007; 361: 528-532
120. Gupta SK, Kumar B, Nag TC, et al. Curcumin prevents experimental diabetic retinopathy in rats through its hypoglycemic, antioxidant, and anti-inflammatory mechanisms. J Ocul harmacol Ther 2011; 27: 123-130
121. Patumraj S, Wongeakin N, Sridulyakul P, Jariyapongskul A, Futrakul N, Bunnag S. Combined effects of curcumin and vitamin C to protect endothelial dysfunction in the iris tissue of STZ-induced diabetic rats. Clin Hemorheol Microcirc 2006; 35: 481-489.
122. Kumar PA, Suryanarayana P, Reddy PY, Reddy GB. Modulation of alpha-crystallin chaperone activity in diabetic rat lens by curcumin. Mol Vis 2005; 11: 561-568.
123. Yokoyama H, Okudaira M, Otani T, et al. Higher incidence of diabetic nephropathy in type 2 than in type 1 diabetes in early-onset diabetes in Japan. Kidney Int 2000; 58: 302-311.
124. Aurell M, Björck S. Determinants of progressive renal disease in diabetes mellitus. Kidney Int Suppl 1992; 36: S38-S42.
125. Keane WF, Kasiske BL, O'Donnell MP. Hyperlipidemia and the progression of renal disease. Am J Clin Nutr 1988; 47: 157-160.
126. Suresh Babu P, Srinivasan K. Amelioration of renal lesions associated with diabetes by dietary curcumin in streptozotocin diabetic rats. Mol Cell Biochem 1998; 181: 87-96.
127. Ha H, Kim KH. Pathogenesis of diabetic nephropathy: the role of oxidative stress and protein kinase C. Diabetes Res Clin Pract 1999; 45: 147-151.
128. Sharma S, Kulkarni SK, Chopra K. Curcumin, the active principle of turmeric (Curcuma longa), ameliorates diabetic nephropathy in rats. Clin Exp Pharmacol Physiol 2006; 33: 940-945.
129. Murugan P, Pari L. Influence of tetrahydrocurcumin on hepatic and renal functional markers and protein levels in experimental type 2 diabetic rats. Basic Clin Pharmacol Toxicol 2007; 101: 241-245.
130. Chiu J, Khan ZA, Farhangkhoee H, Chakrabarti S. Curcumin prevents diabetes-associated abnormalities in the kidneys by inhibiting p300 and nuclear factor-kappaB. Nutrition 2009; 25: 964-972.
131. Kurien BT. Inhibition of p300 and nuclear factor-kappaB by curcumin and its role in diabetic nephropathy. Nutrition 2009; 25: 973-974.
132. Soetikno V, Watanabe K, Sari FR, et al. Curcumin attenuates diabetic nephropathy by inhibiting PKC-α and PKC-β1 activity in streptozotocin-induced type I diabetic rats. Mol Nutr FoodRes 2011; 55: 1655-1665.
133. Ma J, Phillips L, Wang Y, Dai T, LaPage J, Natarajan R, Adler SG. Curcumin activates the p38MPAK-HSP25 pathway in vitro but fails to attenuate diaetic nephropathy in DBA2J mice despite urinary clearance documented by HPLC. BMC Complement Altern Med 2010; 10: 67.
134. Tikoo K, Meena RL, Kabra DG, Gaikwad AB. Change in posttranslational modifications of histone H3, heat-shock protein-27 and MAP kinase p38 expression by curcumin in treptozotocininduced type I diabetic nephropathy. Br J Pharmacol 2008; 153: 1225-1231.
135. Sidhu GS, Mani H, Gaddipati JP, et al. Curcumin enhances wound healing in streptozotocin induced diabetic rats and genetically diabetic mice. Wound Repair Regen 1999; 7: 362-374.
136. Merrell JG, McLaughlin SW, Tie L, Laurencin CT, Chen AF, Nair LS. Curcumin-loaded poly(epsilon-caprolactone) nanofibres: diabetic wound dressing with anti-oxidant and anti-inflammatory properties. Clin Exp Pharmacol Physiol 2009; 36: 1149-1156.
137. Sharma S, Kulkarni SK, Agrewala JN, Chopra K. Curcumin attenuates thermal hyperalgesia in a diabetic mouse model of neuropathic pain. Eur J Pharmacol 2006; 536: 256-261.
138. Sharma S, Chopra K, Kulkarni SK. Effect of insulin and its combination with resveratrol or curcumin in attenuation of diabetic neuropathic pain: participation of nitric oxide and TNF-alpha. Phytother Res 2007; 21: 278-283.
139. Biessels GJ, Gispen WH. The impact of diabetes on cognition: what can be learned from rodent models? Neurobiol Aging 2005; 26(Suppl 1): 36-41.
140. Sima AA, Kamiya H, Li ZG. Insulin, C-peptide, hyperglycemia, and central nervous system complications in diabetes. Eur J Pharmacol 2004; 490: 187-197.
141. Aragno M, Parola S, Brignardello E, et al. Dehydroepiandrosterone prevents oxidative injury induced by transient ischemia/reperfusion in the brain of diabetic rats. Diabetes 2000; 49: 1924-1931.
142. Arvanitakis Z, Wilson RS, Bienias JL, Evans DA, Bennett DA. Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function. Arch Neurol 2004; 61: 661-666.
143. Fukui K, Onodera K, Shinkai T, Suzuki S, Urano S. Impairment of learning and memory in rats caused by oxidative stress and aging, and changes in antioxidative defense systems. Ann N Y Acad Sci 2001; 928: 168-175.
144. Kuhad A, Chopra K. Curcumin attenuates diabetic encephalopathy in rats: behavioral and biochemical evidences. Eur J Pharmacol 2007; 576: 34-42.
145. Rastogi M, Ojha RP, Rajamanickam GV, Agrawal A, Aggarwal A, Dubey GP. Curcuminoids modulates oxidative damage and mitochondrial dysfunction in diabetic rat brain. Free Radic Res 2008; 42: 999-1005.
146. Pari L, Murugan P. Tetrahydrocurcumin prevents brain lipid peroxidation instreptozotocin-induced diabetic rats. J Med Food 2007; 10: 323-329.
147. Lakshmanan AP, Watanabe K, Thandavarayan RA, et al. Curcumin attenuates hyperglycaemia-mediated AMPK activation and oxidative stress in cerebrum of streptozotocin-induced diabetic rat. Free Radic Res 2011; 45: 788-795.
148. Radi R, Beckman JS, Bush KM, Freeman BA. Peroxynitriteinduced membrane lipid peroxidation: the cytotoxic potential of superoxide and nitric oxide. Arch Biochem Biophys 1991; 288: 481-487.
149. Peeyush Kumar T, Antony S, Soman S, Kuruvilla KP, George N, Paulose CS. Role of curcumin in the prevention of cholinergic mediated cortical dysfunctions in streptozotocin-induced diabetic rats. Mol Cell Endocrinol 2011; 331: 1-10.
150. Peeyush KT, Gireesh G, Jobin M, Paulose CS. Neuroprotective role of curcumin in the cerebellum of streptozotocin-induced diabetic rats. Life Sci 2009; 85: 704-710.
151. Kumar TP, Antony S, Gireesh G, George N, Paulose CS. Curcumin modulates dopaminergic receptor, CREB and phospholipase c gene expression in the cerebral cortex and cerebellum of streptozotocin induced diabetic rats. J Biomed Sci 2010; 17: 43.